
Catalog #: PEH1331



## **Summary**

Name	ΡΚΙ-β/ΡΚΙΒ
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/µg as determined by LAL test.
Construction Accession #	Recombinant Human CAMP-dependent Protein Kinase Inhibitor Beta is produced by our E.coli expression system and the target gene encoding Met1-Lys78 is expressed with a 6His tag at the N-terminus. Q9C010
Host	E.coli
Species	Human
Predicted Molecular Mass	10.6 KDa
Formulation	Supplied as a 0.2 µm filtered solution of 20mM Tris-HCl, 100mM NaCl, 1mM DTT, 20% Glycerol, pH 8.0.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at $\leq$ -70°C, stable for 6 months after receipt. Store at $\leq$ -70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	

## **SDS-PAGE** image



# Background

**Alternative Names** 

cAMP-Dependent Protein Kinase Inhibitor Beta; PKI-beta; PKIB; PRKACN2

# Product Name: Recombinant Human PKI-Beta (N-6His) Catalog #: PEH1331



Background

cAMP-Dependent Protein Kinase Inhibitor  $\beta$  (PKI- $\beta$ ) is a member of the PKI family. As a member of the cAMP-dependent protein kinase inhibitor family, It has been shown that PKI- $\beta$  is an extremely potent competitive inhibitor of cAMP-dependent protein kinase activity; this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains. It may play a role in the protein kinase A (PKA) pathway by interacting with the catalytic subunit of PKA, and overexpression of this gene may play a role in prostate cancer.

#### Note

For Research Use Only, Not for Diagnostic Use.